Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial
- Karim Fizazi
- , Pablo González Mella
- , Daniel Castellano
- , Jose N. Minatta
- , Arash Rezazadeh Kalebasty
- , David Shaffer
- , Juan C. Vázquez Limón
- , Héctor M. Sánchez López
- , Andrew J. Armstrong
- , Lisa Horvath
- , Diogo A. Bastos
- , Neha P. Amin
- , Jia Li
- , Keziban Unsal-Kacmaz
- , Margitta Retz
- , Fred Saad
- , Daniel P. Petrylak
- , Russell K. Pachynski
- Section of Molecular Oncology & Developmental Therapeutics
- Roy and Diana Vagelos Division of Biology & Biomedical Sciences (DBBS)
- DBBS - Cancer Biology
- DBBS - Immunology
- DBBS - Molecular Cell Biology
- Institute of Clinical and Translational Sciences (ICTS)
- Bursky Center for Human Immunology and Immunotherapy
- Siteman Cancer Center
- Mentorship to Enhance Development in Academia Program
Research output: Contribution to journal › Article › peer-review
55
Link opens in a new tab
Scopus
citations